Resources

For this Q&A blog, BIA sat down with Annnelise Vuidepot, Chief Technology Officer at Immunocore, to find out about her journey with the company, from its inception to the present day.

Cellestial Health, a pioneering pharmaceutical development spin-out from the University of Cambridge, has closed a £515,000 pre-seed equity funding round to accelerate the development of novel therapeutics targeting astrocytes, an often-overlooked cell type in the brain, with the first indication of Parkinson’s disease.

The UK makes a landmark deal with the US in another week of biotech innovation.

BIA publishes its 10-year Vision for the UK life science sector, the culmination of 18 months of research and engagement with members and the broader life science ecosystem.

BIA is pleased to announce the appointment of Lucy Foley, Chief Technology Officer at eXmoor Pharma, as Vice Chair of its Manufacturing Advisory Committee (MAC).

Microbiotica has presented new data on the mechanism of action of MB310, its product in development as a treatment for ulcerative colitis (UC), at Digestive Disease Week (DDW) 3rd – 6th May in San Diego.

Coulter Partners successfully completed a search assignment for Tozaro and is pleased to announce the placement of Dr. Jason Slingsby, MBA as Chief Executive Officer.

We are calling on the UK government to mandate pension funds to invest in high-growth UK sectors, as new data from its latest report shows British pension schemes are still missing from the biggest biotech deals. 

Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, recently partnered with MTIP and Coramaze Technologies (Coramaze) and is pleased to announce the placement of Rob ten Hoedt as Chair of Coramaze’s Board of Directors.

Alchemab Therapeutics (Alchemab) today announces that it has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s first-in-class IND-ready programme for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.

Symbiosis, a global biopharmaceutical CMO specialising in the sterile fill finish of injectable drug products has been awarded a 2025 King’s Award for Enterprise in the International Trade category.

ELRIG, a not-for-profit, volunteer-led organisation dedicated to the global drug discovery community, has revealed the keynote speakers for its flagship event, Drug Discovery 2025

Ikarovec, which is developing field-changing bicistronic gene therapies for ophthalmic diseases, appoints Dr Thomas Ciulla, expert in ophthalmology drug development, as President and CEO.

Expanding Apprenticeship Pathways - Supporting RNA Medicines, oligos, Quality, Digital and Automation and Manufacturing through ATAC.

This week I highlight innovation across the sector and call on pension funds to be mandated to support our industry.